Clinical Research Directory

Inclusion Criteria: * Healthy female individuals aged ≥18 and ≤40 years at time of screening. * Regular menstrual cycle between 21 and 35 days * Menstrual period of 3 to 7 days * With primary dysmenorrhea defined as a visual analog score (VAS) for pain of ≥4 in the 3 previous months (reported) and at cycle 0 (measured) * BMI is ≥ 18.5 and \< 30 kg/m2 * Females of child-bearing potential must have a negative baseline pregnancy test and agree to use a medically approved method of birth control for the duration of the study. Females not of child-bearing potential (i.e., surgically sterile or post-menopausal ≥12 months) are exempt from this criterion. * Willing to complete online surveys at scheduled time points. * Agrees to maintain current lifestyle habits (diet, physical activity, medications, supplements, and sleep) as much as possible throughout the study. * Provides voluntary, written, informed consent to participate in the study prior to any study procedures. * Has reliable access to internet and a smartphone or computer capable of completing electronic surveys and attending virtual check-ins. * Has an appropriate wearable device (Garmin, Oura, Whoop, Apple Watch, Samsung Watch, Google Health devices) and is willing to share data. Exclusion Criteria: * Pregnant, breastfeeding, or planning to become pregnant during the study. * Underlying diseases, e.g., endometriosis, fibroids (myomas) and pelvic tumor, adenomyosis, endometrial polyps, and pelvic inflammatory disease, and finally, any kind of gynecologic surgery (laparotomy or laparoscopic surgery of cysts, tumors, and intra pelvic adhesions) * Irregular menstrual cycle defined as cycle length \<21 or \>35 days, metrorrhagia, or oligomenorrhea * Anyone who has started, changed, or stopped taking hormonal birth control in the last three months and has a planned insertion or replacement of an IUD in the next 3 months * Regular use of NSAIDs (defined as use ≥3 days/week for ≥3 months) for indications other than dysmenorrhea (e.g., chronic inflammatory or rheumatologic conditions), where discontinuation for the study duration is contraindicated per investigator judgment * Unwilling to agree to rescue medication requirements as described in the protocol (see concomitant meds section) * Any significant change in physical activity level (≥1 day/week or ≥30 min/week of vigorous activity) in the 3 months prior to enrollment, or unwillingness to maintain stable physical activity for the study duration * History of cancer, psychological, neurological, hematological, or other clinically significant systemic disorders * History of kidney or liver disease, non-gynecological abdominal or pelvic surgery (e.g., bowel, bladder, appendix, or urological procedures) that could affect or be confused with menstrual pain. * Use of blood thinner, antidiabetic, antiarrhythmic or blood pressure medications. * Using a dietary supplement which could significantly affect parameters followed during the study according to the investigator (i.e ginger (any supplemental form), chasteberry, evening primrose oil, black cohosh, chamomile and any supplement marketed for menstrual health, PMS, or period pain relief) or stopped less than 6 weeks before inclusion or not willing to refrain their consumption during the study * Consumption of food and/or drink and/or condiment containing ginger (gari, pickled ginger, Japanese food, tea or infusion…) defined as more than 4 times per week prior to the study * Do not agree to limit ginger consumption to maximally 4 times a week during the study * Known or suspected food allergy or intolerance or hypersensitivity to any of the study products' ingredient * Ongoing abuse of drugs and/or alcohol and/or medications at the time of enrolment and history of substance abuse within the last 12 months before enrolment * Drinking more than 2 glasses of alcohol per day, every day and without interruption, and not willing to keep their drinking habits unchanged throughout the study * Smoker more than 10 cigarettes per day * Any reason or condition that in the judgment of the clinical investigator(s) may put the subject at unacceptable risk or that may preclude the subject from understanding or complying with the study's requirements * Currently enrolled in any other clinical trial * Unable to give informed consent